Infinity Pharmaceuticals Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Infinity Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Infinity Pharmaceuticals stock.
View analyst ratings for Infinity Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Infinity Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Infinity Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Infinity Pharmaceuticals saw a decline in short interest during the month of July. As of July 15th, there was short interest totaling 4,430,000 shares, a decline of 19.2% from the June 30th total of 5,480,000 shares. Based on an average daily trading volume, of 1,850,000 shares, the short-interest ratio is currently 2.4 days. Approximately 5.1% of the company's shares are sold short.
View Infinity Pharmaceuticals' Short Interest.

Infinity Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Infinity Pharmaceuticals.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) posted its quarterly earnings data on Tuesday, July, 27th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.01. Infinity Pharmaceuticals had a negative trailing twelve-month return on equity of 304.81% and a negative net margin of 2,251.75%.
View Infinity Pharmaceuticals' earnings history.

Infinity Pharmaceuticals' stock was trading at $1.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INFI shares have increased by 163.4% and is now trading at $2.66.
View which stocks have been most impacted by COVID-19.

8 brokerages have issued 1-year price objectives for Infinity Pharmaceuticals' stock. Their forecasts range from $4.00 to $14.00. On average, they expect Infinity Pharmaceuticals' stock price to reach $9.63 in the next twelve months. This suggests a possible upside of 261.8% from the stock's current price.
View analysts' price targets for Infinity Pharmaceuticals or view top-rated stocks among Wall Street analysts.

10 employees have rated Infinity Pharmaceuticals CEO Adelene Q. Perkins on Glassdoor.com. Adelene Q. Perkins has an approval rating of 100% among Infinity Pharmaceuticals' employees. This puts Adelene Q. Perkins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Infinity Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of INFI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Infinity Pharmaceuticals investors own include Continental Resources (CLR), Rex Energy (REXX), Aerie Pharmaceuticals (AERI), Gilead Sciences (GILD), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Novavax (NVAX) and Celldex Therapeutics (CLDX).

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

Infinity Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include New York State Common Retirement Fund (0.08%), Alliancebernstein L.P. (0.02%) and Lindbrook Capital LLC (0.01%).
View institutional ownership trends for Infinity Pharmaceuticals.

INFI stock was purchased by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Alliancebernstein L.P., and Lindbrook Capital LLC.
View insider buying and selling activity for Infinity Pharmaceuticals or or view top insider-buying stocks.

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INFI stock can currently be purchased for approximately $2.66.

Infinity Pharmaceuticals has a market capitalization of $236.00 million and generates $1.72 million in revenue each year. The biotechnology company earns $-40,490,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis.

Infinity Pharmaceuticals employs 23 workers across the globe.

The official website for Infinity Pharmaceuticals is www.infi.com.

Infinity Pharmaceuticals is headquartered at 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138.

Infinity Pharmaceuticals' mailing address is 1100 MASSACHUSETTS AVENUE FLOOR 4, CAMBRIDGE MA, 02138. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]